SCHEMBL3668358

SCHEMBL3668358

CC(=O)N1CCN(c2cc[c]c(C(N)=O)n2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 1/20 0.47
CASP6 P55212 1/20 0.43
GFER P55789 1/20 0.43
CKS1B P61024 1/20 0.43
SKP1 P63208 1/20 0.43
SKP2 Q13309 1/20 0.43
GBA1 P04062 1/20 0.42
SYK P43405 4/20 0.41
ALDH1A1 P00352 3/20 0.41
HSD17B10 Q99714 2/20 0.41
GAA P10253 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
AOC3 Q16853 1/20 0.40
PIK3CD O00329 1/20 0.40
NCF1 P14598 2/20 0.40
HPGD P15428 1/20 0.39
BPTF Q12830 1/20 0.39
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2744970 0.86 PARP1 (0.49) MAP4K4ALDH1A1HSD17B10KDM4E
SCHEMBL3672661 0.85 CKS1B (0.46) MAP4K4CKS1BSKP1SKP2SYK
SCHEMBL3638386 0.85 MAP4K4 (0.50) MAP4K4ALDH1A1HSD17B10KDM4EMAPT
SCHEMBL3629275 0.85 CKS1B (0.47) CKS1BSKP1SKP2SYKALDH1A1
SCHEMBL4965500 0.84 PARP1 (0.46) MAP4K4GFERALDH1A1HSD17B10GAA
SCHEMBL3665112 0.83 CKS1B (0.47) MAP4K4CKS1BSKP1SKP2GBA1
SCHEMBL2744801 0.82 PARP1 (0.47) MAP4K4GFERALDH1A1HSD17B10GAA
SCHEMBL2829654 0.82 HRH3 (0.47)
SCHEMBL2825602 0.82 HRH3 (0.45) GFERSYKALDH1A1GAAHPGD
SCHEMBL3634174 0.81 CKS1B (0.38) MAP4K4CKS1BSKP1SKP2GBA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007097697-A1 THERAPEUTIC QUINOLINE COMPOUNDS THAT ARE 5HT1B MODULATORS ASTRAZENECA AB (SE) 2007-08-30 WO claimed
EP-2155687-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS Via Pharmaceuticals, Inc. (US) 2010-02-24 EP disclosed
US-20090170864-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2009-07-02 US disclosed
US-20090105273-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2009-04-23 US disclosed
US-20090099201-A1 Diacylglycerol Acyltransferase Inhibitors VIA PHARMACEUTICALS, INC. 2009-04-16 US disclosed
US-20090093497-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2009-04-09 US disclosed
WO-2008141976-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS VIA PHARMACEUTICALS, INC. (US) 2008-11-27 WO disclosed
WO-2007097697-A1 THERAPEUTIC QUINOLINE COMPOUNDS THAT ARE 5HT1B MODULATORS ASTRAZENECA AB (SE) 2007-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093497-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, LCAT MAP4K4 2328/4885CASP6 3996/4885GFER 1433/4885
US-20090170864-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, LCAT MAP4K4 2328/4885CASP6 3996/4885GFER 1433/4885
US-20090099201-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, LCAT MAP4K4 2328/4885CASP6 3996/4885GFER 1433/4885
US-20090105273-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, LCAT MAP4K4 2328/4885CASP6 3996/4885GFER 1433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.